Chabio

CHA Biotech (㈜차바이오텍) is a South Korean biotechnology company headquartered in the CHA Bio Complex at 335 Pangyo-ro, Bundang-gu, Seongnam, Gyeonggi Province, with a Seoul office in the P&Polus building, Dosan-daero, Gangnam-gu. The company is organized into business divisions covering cord blood banking (operated under the iCord brand), cell insurance (immune-cell and stem-cell storage services), the Chaum health and wellness center, healthcare IT, CDMO, consulting and genomics. Its stated R&D focus is cell and gene therapy for rare cancers and intractable diseases, with a pipeline built around selecting disease-specific cell lines for customized cell therapeutics.

The CDMO division provides full-cycle GMP manufacturing and testing of advanced biopharmaceuticals (cell and gene therapies) across the United States, Japan and Korea, through subsidiaries including Matica Biotechnology and Matica Bio Labs. The genomics division offers genomic research and diagnostic testing for personalized precision medicine, while the IT division develops digital healthcare services, mobile medical information solutions and hospital information systems using AI and big data. The consulting division sells medical-facility operating models based on the company's "power aging" life center concept.

CHA Biotech sits within a wider affiliate network that includes CMG Pharmaceutical, CHA Healthcare, CHA Care s, CHA AI Healthcare, Kakao Healthcare, Seoul CRO, CHA Meditech, CHA Bio F&C, CHA Logis, Matica Biotechnology and Matica Bio Labs, alongside related institutions CHA Hospital and CHA University. A separate US e-commerce storefront markets Chabio-branded Evercell skincare products containing epidermal stem cell culture media. The company has also been indexed by industry data providers under the former name CHA Bio & Diostech Co., Ltd., classified in pharmaceuticals, biotechnology, gene and cell therapy, and contract research.

Business model

The company operates multiple revenue-generating divisions: fee-based consumer services (cord blood storage under the iCord brand, immune- and stem-cell storage "cell insurance", and the Chaum wellness center), business-to-business contract manufacturing and testing of cell and gene therapies through its CDMO division, genomic testing and diagnostics, healthcare IT development and system operations, and consulting services for medical facility models. Consumer skincare products under the Evercell line are sold through a US online store.

Revenue is generated from consumer service fees for cord blood and cell storage and wellness programs, contract development and manufacturing service contracts in the CDMO business, genomic testing and diagnostic fees, IT development and system operation contracts, consulting fees, and product sales of Evercell skincare items.

Traction

The company reported consolidated first-half revenue of KRW 646.1 billion for 2026 and states a network of approximately 14,000 employees, 1,800 medical staff and 20,000 researchers across 96 institutions in seven countries. Its Japanese regenerative medicine clinic reports more than 5,000 treatment cases.

Latest developments

In 2026 the company published half-year and first-quarter IR materials and held an investor briefing in April. In August 2026 it reported consolidated first-half revenue of KRW 646.1 billion and announced selection for the Ministry of Science and ICT's K-HERO development and support program. It was also selected for the ministry's post-doctoral researcher industry-academia project and its AX One-Stop Voucher program.